14-3-3σ Expression and prognostic value in patients with epithelial ovarian carcinoma: A high throughput tissue microarray analysis

European Journal of Surgical Oncology

Volumn 35, Issue 7, 2009, Pages 763-767

  Mhawech Fauceglia, P ^a   Herrmann, F R ^b   Andrews, C ^c   South, S ^a   Beck, A ^a   Lele, S ^a   Odunsi, K ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

14 3 3 Expression; Epithelial ovarian carcinoma; Prognosis

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; STRATIFIN; EXONUCLEASE; SFN PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER GRADING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; METHYLATION; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; ADENOCARCINOMA; BIOSYNTHESIS; GENETICS; METABOLISM; MIDDLE AGED; OVARY TUMOR; PROGNOSIS; SURVIVAL;

ADENOCARCINOMA; EXONUCLEASES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 66349096940     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2008.10.014     Document Type: Article

References (28)

1. Bite S. Age-specific incidence and mortality rates for ovarian cancer, 1998-2002. J Natl Cancer Inst 98 (2006) 511
2. Korkolopoulou P., Vassilopoulos I., Konstantinidou A.E., et al. The combined evaluation of p27 and ki-67 expression provides independent information on overall survival of ovarian carcinoma patients. Gynecol Oncol 85 (2002) 404-414
3. Khouja M.H., Baekelandt M., Nesland J.M., and Holm R. The clinical importance of ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma. Int J Gynecol Pathol 26 (2007) 418-425
4. Levidou G., Korkolopoulou P., Thymara I., et al. Expression and prognostic significance of cyclin D3 in ovarian adenocarcinomas. Int J Gynecol Pathol 26 (2007) 410-417
5. Konstantinidou A.E., Korkolopoulou P., Vassilopoulos I., et al. Reduced retinoblastoma gene protein to ki-67 ratio is an adverse prognostic indicator for ovarian adenocarcinoma patients. Gynecol Oncol 88 (2003) 369-378
6. Winter III W.E., Maxwell G.L., Tian C., et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 25 (2007) 3621-3627
7. Skirnisdòtir I., and Sorbe B. Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIG0-stages III-IV) epithelial ovarian carcinoma. Int J Oncol 30 (2007) 727-734
8. Wimbeger P., Lehmann N., Kimmig R., et al. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An explatory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie ovarian cancer study group (AGO-AVAR). Gynecol Oncol 106 (2007) 69-74
9. Hermeking H. The 14-3-3 cancer connection. Nat Rev 3 (2003) 931-943
10. Tzivion G., Gupta V.S., Kaplun L., and Balan V. 14-3-3 proteins as potential oncogenes. Semin Cancer Biol 16 (2006) 203-213
11. Hermeking H., and Benzinger A. 14-3-3 proteins in cell cycle regulation. Semin Cancer Biol 16 (2006) 183-192
12. Horie-Inoue K., and Inoue S. Epigenetic and proteolytic inactivation of 14-3-3σ in breast and prostate cancers. Semin Cancer Biol 16 (2006) 235-239
13. Mhawech P., Benz A., Greloz V., et al. Down-regulation of 14-3-3σ in ovary, prostate, and endometrial carcinomas is associated with CpG-methylation. Mod Pathol 18 (2005) 340-348
14. Akahira J.-I., Sugihashi Y., Suzuki T., et al. Decreased expression of 14-3-3σ is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin Cancer Res 10 (2004) 2687-2693
15. Herman J.G., and Baylin S.B. Mechanisms of disease: gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349 (2003) 2042-2054
16. Das P.M., and Singal R. DNA methylation and cancer. J Clin Oncol (2004) 4632-4642
17. Lodygin D., and Hermeking H. Epigenetic silencing of 14-3-3 sigma in cancer. Semin Cancer Biol 16 (2006) 214-224
18. Sato N., Maitra A., Fukushima N., et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 63 (2003) 4158-4166
19. Iacobuzio-Donahue C.A., Maitra A., Olsen M., et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 162 (2003) 1151-1162
20. Shimizu Y., Kamoi S., Amada S., Akiyama F., and Silverberg S.G. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposal system in a series of 421 patients with uniform treatment and follow-up. Cancer 82 (1998) 893-901
21. Creasman W.T. Announcement: FIGO stages: 1988 revision. Gynecol Oncol 35 (1989) 125-127
22. Kononen J., Bubendorf L., Kallioniemi A., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4 (1998) 844-847
23. Kaneuchi M., Sasaki M., Tanaka Y., et al. Expression and methylation status of 14-3-3 sigma gene can characterize the different features of ovarian cancer. Biochem Biophys Res Commun 316 (2004) 1156-1162
24. Mhawech P. 14-3-3 proteins: an update. Cell Res 15 (2005) 228-236
25. Ito K., Suzuki T., Akahira J.-I., et al. 14-3-3σ in endometrial cancer - a possible prognostic marker in early-stage cancer. Clin Cancer Res 11 (2005) 7384-7391
26. Perathoner A., Pirkebner D., Brandacher G., et al. 14-3-3σ Expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Clin Cancer Res 11 (2005) 3274-3279
27. Mhawech-Fauceglia P., Alvarez V., Fischer G., Beck A., and Herrmann F.R. Association of hamartin, 14-3-3 σ, and p27 in predicting pTa/pT1 urothelial bladder carcinomas outcomes. Am J Clin Pathol 129 (2008) 918-923
28. Mhawech-Fauceglia P., Fischer G., alvarez V., Ahmed A., and Herrmann F. Predicting outcome in minimally invasive (T1A and T1B) urothelial bladder carcinoma using a panel of biomarkers; a high throughput tissue microarray analysis. BJU Int 100 (2007) 1182-1187